Home / Community / News / News

News

05/18/2016 - 8:55am

MDF's Interim Chief Science Officer, Dr. John Porter, brings a wealth of experience to MDF as a former academic researcher, program director at the National Institutes of health (NIH) and Chief Executive Officer of a patient advocacy organization. John offered his thoughts recently on the importance of patient advocacy in drug development.

04/02/2016 - 7:56pm

Researchers from the University of Costa Rica and the University of Glasgow teamed up to investigate the DNA mutation causing myotonic dystrophy type 1 (DM1). They found that polymorphism in the MSH3 mismatch repair gene is associated with the levels of somatic instability of the expanded CTG repeat in the blood DNA of myotonic dystrophy type 1 patients. 

04/02/2016 - 7:31pm

Dr. Dixon at the University of Utah has been awarded a 2016-2017 postdoctoral fellowship for her research applying fMRI to evaluate connectivity networks in the brains of children with congenital-onset myotonic dystrophy (CDM). Read more here about the work of Dr. Dixon and her colleagues.

04/02/2016 - 7:22pm

Dr. John Porter, former Program Director of Neuromuscular Disease at the National Institute of Neurological Disorders and Stroke (NINDS), a component of the National Institutes of Health (NIH), has joined MDF as its Interim Chief Science Officer. Dr. Sharon Hesterlee, who formerly filled this position, will remain active as a member of MDF’s Scientific Advisory Committee.

03/10/2016 - 7:04am

MDF’s Outreach Director and Support Group Trainer, Leslie Krongold, has moved on from MDF in order to realize a dream that will also benefit the DM community. Read more here to learn about the podcast program she is launching, Glass Half Full, and find out how MDF is continuing to expand on the resources she helped us build.

Partners

© Myotonic Dystrophy Foundation. All rights reserved.